Molecular Diagnostic Firm ImmunArray Raises $10M
July 13, 2016 | Israeli molecular diagnostic company ImmunArray has closed a Series B financing round of $10 million led by private investment firm Exigent. With offices in Rehovot, Israel and Richmond, Virginia, ImmunArray has developed novel blood tests and pioneers new and more accurate ways to diagnose autoimmune diseases such as lupus as well as traumatic brain injury (TBI). The company was founded in 2006 based on iCHIP technology licensed from the Weizmann Institute of Science. iCHIP technology can determine the presence of a specific set of molecular biomarkers that are linked to particular disease or condition.